Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. | Semantic Scholar
Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study | Scientific Reports
Table 1 from Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. | Semantic Scholar
Life on a Blood Thinner: Insights and Advice from an Anticoagulant Specialist - YouTube
Remedial dosing recommendation for delayed or missed rivaroxaban doses for patients with non-valvular atrial fibrillation based on Monte Carlo simulation | medRxiv
Xa Inhibitors - Apixaban and Rivaroxaban Oral Xa ... | GrepMed
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation | Scientific Reports
Rivaroxaban: A New Oral Anticoagulant
Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist | touchCARDIO
Safety Profile - NVAF | XARELTO® (rivaroxaban) HCP
JCM | Free Full-Text | Etiology of Ischemic Strokes of Patients with Atrial Fibrillation and Therapy with Anticoagulants
Xarelto Full Prescribing Information, Dosage & Side Effects | MIMS Philippines
Optimal Rivaroxaban Dose in Asian Patients With Atrial Fibrillation and Normal or Mildly Impaired Renal Function | Stroke
Effectiveness and Safety of Standard- and Low-Dose Rivaroxaban in Asians With Atrial Fibrillation | Journal of the American College of Cardiology
AHA 2016: Low-dose rivaroxaban reduces clinically significant bleeding in PCI patients with atrial fibrillation - Cardiovascular News
Pediatric VTE | XARELTO® (rivaroxaban) HCP
Safety Profile - VTE Prophylaxis | XARELTO® (rivaroxaban) HCP
Treatment Considerations | XARELTO® (rivaroxaban) HCP
Target-Specific Oral Anticoagulants
Direct current cardioversion and thromboprophylaxis in atrial fibrillation - The British Journal of Cardiology
Doses Studied in RCTs of Rivaroxaban and Dabigatran - Prevention and Treatment of Venous Thromboembolism - Advances in Anticoagulation for Venous Thromboembolism
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants - ScienceDirect
Dose Regimens in Approved Rivaroxaban Indications. 1 | Download Table
